Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
You may also be interested in...
The Bill & Melinda Gates Foundation has invested $55m in an infectious disease collaboration with Germany’s BioNTech that could reach up to $100m in total funding.
In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed cellular therapy, after announcing tie-up with Adaptive Biotechnologies.
Two studies published in Nature July 5 showed that personalized cancer vaccines from BioNTech and Neon Therapeutics delivered potent immune responses in patients with melanoma. Both companies are moving forward with new studies.